Juvenescence

Juvenescence develops medicines that target core aging mechanisms to prevent age-related disease. Their programs span small molecules, biologics, and cell therapies, with a stated commitment to having five medicines in Phase I or II trials by 2025. The focus is on early disease intervention rather than late-stage treatment, leveraging mechanisms such as PAI-1 inhibition that recently completed a Phase 1 trial.

Co-Founder Dr. Greg Bailey drives strategy, drawing on his experience leading the $26 billion in acquisitions behind Pfizer-Medivation and Pfizer-Biohaven. The R&D leadership includes Gill Dines as Chief Scientific Officer and newly appointed CTO Eileen Jennings-Brown, supported by a team the firm says has over 150 years of combined pharma experience and multiple prior drug approvals.

Juvenescence is not a single-family office or a university spinout; it operates as an investment-driven biotech platform. Its founders come from pharma dealmaking and product approvals, not a single liquidity event, which gives the firm a hybrid structure: it builds and advances clinical assets while pursuing secondary exits that have returned 200x to investors on certain past transactions.

Juvenescence lists a registered address in New York and the British Virgin Islands. It maintains an active scientific and investor presence in the UK and recently strengthened its UAE operations by joining Masdar City’s Life Science Innovation Cluster in February 2026. The team has presented at conferences in London, Singapore, and the UAE.

Juvenescence does not publicly disclose a separate philanthropic vehicle. Its core mission — extending healthy lifespan through preventive medicine — is framed as a public-health contribution in its own right, but there is no named foundation or charitable entity directly linked to the firm in available materials.